5-MeO-DMT for Depression and Anxiety: What the Evidence Shows

What Is 5-MeO-DMT, and Why Is It Being Studied for Depression and Anxiety?

5-MeO-DMT is a short-acting tryptamine psychedelic found in certain plants and, famously, in the defensive secretion of the Colorado River toad (Incilius alvarius a.k.a. Bufo Alvarius). It is chemically related to DMT and psilocybin, but it behaves quite differently in practice. Where a psilocybin session runs six to eight hours, a 5-MeO-DMT experience typically lasts 30 to 90 minutes from onset to return to baseline. That difference is the reason researchers began paying serious attention to it as a candidate for treating depression and anxiety.

The logic is practical. Psychedelic-assisted therapy is expensive largely because it consumes an entire clinical day. A compound that produces a comparably profound experience in under an hour could, at least in principle, fit into treatment models that already exist. Alan Davis, one of the researchers who has published most extensively in this area, has made exactly this point about the compound’s short duration and its potential fit with conventional therapy session structures.

The subjective character of the experience is also distinct. Rather than the visual and narrative quality people associate with psilocybin or LSD, high-dose 5-MeO-DMT tends to produce a complete dissolution of the sense of self, often with no memory of visual content at all. Participants frequently describe it in terms of total loss of ordinary reference points. This is not a gentle compound, and it is not one that lends itself to casual exploration.

What Does the Clinical Research Actually Show?

The most significant development is the Phase 2b trial of BPL-003, an intranasal formulation of mebufotenin (5-MeO-DMT) benzoate developed by Beckley Psytech and atai Life Sciences. The topline results, announced in July 2025, are the strongest controlled evidence available for this compound.

The study ran across 38 sites in six countries and enrolled 193 participants with moderate-to-severe treatment-resistant depression. It was quadruple-masked, meaning participants, clinicians, raters, and the study team were all blinded, and it compared a single 12mg dose and a single 8mg dose against a 0.3mg low-dose comparator. Depression symptoms were measured with the Montgomery-Asberg Depression Rating Scale at days 2, 8, 29, and 57.

At day 29, the 12mg dose produced a statistically significant reduction in depression symptoms compared to the comparator, and the trial met its primary endpoint along with all key secondary endpoints. The companies reported no drug-related serious adverse events, with more than 99 percent of treatment-emergent adverse events rated mild or moderate, and no suicide-related safety signals in either active dose group. Notably, the 8mg dose was selected to advance into Phase 3, which tells you the researchers judged the efficacy-to-tolerability tradeoff at the lower dose to be more favorable.

One practical detail matters here. Patients in the earlier Phase 2a work were discharged, on average, in under two hours. That is a fundamentally different logistical proposition from the full-day model that psilocybin and MDMA protocols require, and it is a large part of why this compound is attracting serious pharmaceutical investment.

Here is the limitation, though. One positive Phase 2b trial is a meaningful signal, not a settled conclusion. The primary endpoint was measured at day 29. What happens at six months, or at twelve, in a controlled setting is simply not yet known. Phase 3 has not reported.

What Do the Survey and Observational Studies Say?

Before the clinical trials, most of what was known about 5-MeO-DMT for depression and anxiety, including its role in 5-MeO-DMT depression anxiety treatment, came from surveys and naturalistic observation. This evidence is weaker by design, but it is remarkably consistent, and it is worth understanding on its own terms.

A 2019 study led by Davis and colleagues at Johns Hopkins, published in the American Journal of Drug and Alcohol Abuse, surveyed people who had used 5-MeO-DMT in structured group settings. Among respondents who reported a prior depression diagnosis, 80 percent said their depression had improved following use. Among those with a prior anxiety diagnosis, 79 percent reported improvement. A small minority reported no change, and a very small minority reported worsening. Improvement was associated with the intensity of the mystical-type experience and with how personally meaningful participants rated the session.

A separate observational study by Uthaug and colleagues followed 42 people who inhaled vapor from dried toad secretion in a naturalistic setting. Ratings of depression, anxiety, and stress dropped in the days after the session and continued to decline over four weeks, at which point the reductions reached statistical significance. Participants who reported stronger ego dissolution showed lower levels of depression and stress at follow-up.

This is where things get more nuanced. Survey and observational data cannot separate the effect of the compound from the effect of expectation, from the effect of the group setting, or from the effect of self-selection. People who have a bad experience are less likely to fill out a follow-up questionnaire. People who traveled to a retreat and paid money for it have a strong motivation to report benefit. Those biases are real, and they are large enough that no responsible reading of this literature treats an 80 percent improvement rate as a predicted outcome. Treat it as a signal worth investigating, which is precisely what the clinical trials are now doing.

How Does 5-MeO-DMT Compare to Psilocybin and Ketamine for These Conditions?

For depression specifically, ketamine has the deepest evidence base and is legally available now through clinics across the United States. Psilocybin has a larger and more mature body of controlled research for both depression and end-of-life anxiety, with multiple randomized trials behind it. Against that, 5-MeO-DMT has one strong Phase 2b result.

That ranking will not necessarily hold. But as things stand in 2026, anyone weighing options for depression or anxiety is choosing between one modality with a decade of trial data, one that is legally accessible today, and one that is still in the pipeline. If you want a fuller comparison of the two most-studied options, our breakdown of psilocybin versus ketamine therapy covers the mechanisms and the tradeoffs in detail.

Where 5-MeO-DMT may eventually differentiate itself is speed and cost of delivery, not necessarily depth of effect. A protocol that fits in a two-hour clinic visit is a different kind of intervention from one that requires a full day, a private room, and two trained monitors.

What Are the Real Risks?

The risks with this compound are not theoretical, and they deserve more weight than the enthusiasm currently surrounding it.

Cardiovascular and physiological risk. 5-MeO-DMT produces sharp increases in heart rate and blood pressure during onset. For anyone with an underlying cardiac condition, this is a serious concern.

Serotonin syndrome risk with medication interactions. Combining 5-MeO-DMT with an MAOI is genuinely dangerous and has been associated with fatalities. Interactions with SSRIs and other serotonergic medications require careful clinical evaluation. This is not a compound where you can reason your way through your own medication list. Our overview of psychedelic therapy contraindications covers the categories of people who should stop before going further.

Intensity and psychological risk. The complete ego dissolution that many people seek from this compound is also what makes it destabilizing. In naturalistic settings, a substantial minority of participants report challenging experiences. Without skilled support before, during, and after, that difficulty can go unprocessed.

Dose imprecision outside clinical settings. Toad secretion varies enormously in 5-MeO-DMT content depending on the animal, the collection method, and storage. Synthetic 5-MeO-DMT allows precise dosing; secretion does not. This is one of several reasons the clinical trials use a standardized synthetic formulation rather than the traditional material.

Conservation and ethics. Demand for toad secretion has placed real pressure on Sonora Desert Toad populations. Synthetic 5-MeO-DMT is chemically identical and does not involve an animal.

It is worth saying plainly: 5-MeO-DMT is a Schedule I substance in the United States, and there is no legal therapeutic pathway to it outside of a clinical trial.

Who Should Consider 5-MeO-DMT, and Who Should Wait?

For most people dealing with depression or anxiety in 2026, the real answer is that 5-MeO-DMT is not the right starting point. The evidence is early, access is limited to trials, and better-supported options exist. If you have exhausted conventional treatment, the practical paths available today are ketamine therapy, legal psilocybin services in Oregon and Colorado, or enrolling in a clinical trial.

The people for whom 5-MeO-DMT becomes worth serious attention are those with treatment-resistant depression who have already worked through the more established options and who are willing to engage with a clinical trial protocol. That is a narrower group than the current online conversation suggests.

What we can say with confidence is that this compound is no longer fringe. The Phase 2b data are real, the regulatory path is active, and the research is moving quickly. What we cannot say is that it works, in the sense that word carries after Phase 3 and regulatory review. That gap is where careful judgment belongs.